Rc(=o)n Containing (i.e., Carboxamide) (r Is C Or H) Patents (Class 514/563)
-
Patent number: 12084399Abstract: The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.Type: GrantFiled: July 1, 2021Date of Patent: September 10, 2024Assignee: NUFORMIX TECHNOLOGIES LIMITEDInventors: Joanne Holland, Christopher Frampton
-
Patent number: 11826471Abstract: Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.Type: GrantFiled: August 12, 2021Date of Patent: November 28, 2023Assignee: ARENA PHARMACEUTICALS, INC.Inventors: Zezhi Jesse Shao, Raizza Berania Florida, Ching-Yuan Li, Lee Alani Selvey
-
Patent number: 11766421Abstract: Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.Type: GrantFiled: September 21, 2018Date of Patent: September 26, 2023Assignee: SURFACE OPHTHALMICS, INC.Inventors: Dennis Elias Saadeh, Kamran Hosseini
-
Patent number: 11730716Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.Type: GrantFiled: May 8, 2015Date of Patent: August 22, 2023Assignee: KIORA PHARMACEUTICALS GMBHInventors: Stefan Sperl, Franz Obermayr
-
Patent number: 11607397Abstract: Methods for the treatment of leptomeningeal disease in a pediatric patient. The leptomeningeal disease may be leptomeningeal, disseminated, and/or multicentric disease (LDM) and may be associated with one or more primary CNS tumors or one or more low-grade gliomas (LGGs). The method includes administering to a patient a plurality of extraneous antineoplastons.Type: GrantFiled: June 11, 2018Date of Patent: March 21, 2023Assignee: Stanislaw R. BurzynskiInventor: Stanislaw R. Burzynski
-
Patent number: 11583535Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: GrantFiled: August 20, 2020Date of Patent: February 21, 2023Assignee: OCCURX PTY LTDInventors: Darren James Kelly, David Stapleton
-
Patent number: 11578032Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.Type: GrantFiled: February 13, 2019Date of Patent: February 14, 2023Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventor: Thomas Scanlan
-
Patent number: 11571403Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.Type: GrantFiled: February 4, 2020Date of Patent: February 7, 2023Assignee: Eiger BioPharmaceuticals, Inc.Inventors: Xiaofeng Xiong, David A. Cory
-
Patent number: 11478437Abstract: The present invention is directed to compositions and formulations for hair growth. The non-aqueous, preservative-free formulations are useful for the growth of hair, eyebrows and eyelash in a variety of setting. Also provided herein are non-aqueous, preservative-free formulations and methods for the treatment of dry-eye and related symptoms.Type: GrantFiled: June 30, 2017Date of Patent: October 25, 2022Assignee: JENIVISION INC.Inventors: Weizhen Wang, David F. Woodward
-
Patent number: 11427530Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.Type: GrantFiled: February 11, 2019Date of Patent: August 30, 2022Assignee: VISTAGEN THERAPEUTICS, INC.Inventors: Daniel Levin, Peter Leeming, Emerich Eisenreich, Xuejun Karl Liu
-
Patent number: 11426371Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.Type: GrantFiled: April 27, 2018Date of Patent: August 30, 2022Assignees: University of Virginia Patent Foundation, Universität de Barcelona, Consejo Superior de Investigaciones Cientificas (CSIC)Inventors: Thomas P. Loughran, Jr., Gemma Fabrias, Jose Luis Abad, Josefina Casas, David J. Feith, Su-Fern Tan, Jennifer M. Pearson, Antonio Delgado Cirilo
-
Patent number: 11331289Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.Type: GrantFiled: September 14, 2018Date of Patent: May 17, 2022Assignees: CEVA SANTE ANIMALE, UNION THERAPEUTICS A/SInventors: Jérôme Guyonnet, Claudine Zemiriline, Pascal Butty
-
Patent number: 11266645Abstract: Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.Type: GrantFiled: May 3, 2019Date of Patent: March 8, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
-
Patent number: 11077192Abstract: A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.Type: GrantFiled: June 12, 2019Date of Patent: August 3, 2021Assignee: DUSA PHARMACEUTICALS, INC.Inventors: Scott Lundahl, Michael Guttadauro
-
Patent number: 11007160Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.Type: GrantFiled: April 16, 2014Date of Patent: May 18, 2021Assignee: Monash UniversityInventors: Johanna Elisabeth Fraser, David Andrew Jans, Kylie Michelle Wagstaff
-
Patent number: 11001564Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.Type: GrantFiled: September 13, 2017Date of Patent: May 11, 2021Assignee: Arbutus Biopharma CorporationInventors: Andrew G. Cole, Steven Kultgen
-
Patent number: 10980735Abstract: The present invention relates to a skin external composition containing an extract of green tea produced by an extreme light-shielding cultivation method, which is distinguished from a conventional light-shielding cultivation method of green tea. More specifically, the present invention relates to a skin external composition, which contains an extract of green tea cultivated by extreme light-shielding, in which the amino acid content is remarkably increased by cultivating the green tea by a light-shielding cultivation under a light-shielding rate of 99% or more, thereby obtaining more excellent skin moisturizing, skin protecting, and anti-aging effects.Type: GrantFiled: September 21, 2017Date of Patent: April 20, 2021Assignee: AMOREPACIFIC CORPORATIONInventors: Yeong Ran Lee, Jun Seong Park, Eun Soo Lee, Nok Hyun Park
-
Patent number: 10959970Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.Type: GrantFiled: July 18, 2019Date of Patent: March 30, 2021Assignee: Nogra Pharma LimitedInventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
-
Patent number: 10905667Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.Type: GrantFiled: July 24, 2018Date of Patent: February 2, 2021Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
-
Patent number: 10881624Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: September 12, 2018Date of Patent: January 5, 2021Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10881657Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: March 20, 2019Date of Patent: January 5, 2021Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10799497Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: January 7, 2020Date of Patent: October 13, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10786469Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: November 12, 2019Date of Patent: September 29, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10780066Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.Type: GrantFiled: August 31, 2018Date of Patent: September 22, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10688042Abstract: A gel for topical application for alleviating food cravings is disclosed, which includes the steps of: periodically applying a gel topically to a user's skin, wherein said gel comprises: about 45.0 percent by weight of deionized water; about 10.0 percent by weight of benzyl alcohol; about 40.0 percent by weight of ethyl alcohol; about 0.2 percent by weight of tocopherol acetate; about 0.15 percent by weight of docosahexaenoic acid (DHA); about 1.15 percent by weight of resveratrol; about 1.0 percent by weight of a cross-linked polyacrylic acid copolymer; about 0.1 percent by weight of ethylenediaminetetraacetic acid (EDTA); about 200 ?L of lemon essential oil; and, from about 100 ?L to 200 ?L of triethanolamine.Type: GrantFiled: October 15, 2019Date of Patent: June 23, 2020Inventor: Antonino Cavallaro
-
Patent number: 10596167Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: September 17, 2018Date of Patent: March 24, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10555950Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.Type: GrantFiled: April 12, 2016Date of Patent: February 11, 2020Assignee: SATIOGEN PHARMACEUTICALS, INC.Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
-
Patent number: 10548857Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.Type: GrantFiled: September 11, 2018Date of Patent: February 4, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10532073Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.Type: GrantFiled: June 26, 2019Date of Patent: January 14, 2020Assignee: Io Therapeutics, Inc.Inventors: Roshantha A. Chandraratna, Martin E. Sanders
-
Patent number: 10420738Abstract: An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ?F508-CFTR, or another mutation of class II.Type: GrantFiled: December 15, 2015Date of Patent: September 24, 2019Assignee: INSTYTUT BIOCHEMII I BIOFIZYKI PANInventors: Norbert Odolczyk, Piotr Zielenkiewicz, Grzegorz Wieczorek, Aleksander Edelman, Danielle Tondelier, Janine Fritsch
-
Patent number: 10406086Abstract: Moisturizers including an acyl neutral amino acid having an acyl group with a carbon atom number of 2 to 18, and salts thereof, and cosmetics containing such a moisturizer promote the production of moisturizing-related proteins, such as filaggrin, involucrin, transglutaminase 1, keratin 10, and loricrin, and provide a moisturizing effect.Type: GrantFiled: February 26, 2018Date of Patent: September 10, 2019Assignee: Ajinomoto Co., Inc.Inventors: Gaku Hattori, Hiroji Ishii, Fumie Honkawa
-
Patent number: 10398667Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.Type: GrantFiled: January 16, 2018Date of Patent: September 3, 2019Assignee: Nogra Pharma LimitedInventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
-
Patent number: 10111911Abstract: Compositions include one or more unsaturated fatty acids and one or more nitric oxide releasing compounds. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.Type: GrantFiled: February 23, 2017Date of Patent: October 30, 2018Assignee: Nestec S.A.Inventor: Yuanlong Pan
-
Patent number: 10098860Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.Type: GrantFiled: July 19, 2017Date of Patent: October 16, 2018Assignee: Cipla LimitedInventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
-
Patent number: 9968576Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.Type: GrantFiled: October 24, 2014Date of Patent: May 15, 2018Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGYInventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
-
Patent number: 9849144Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.Type: GrantFiled: August 27, 2014Date of Patent: December 26, 2017Assignee: Healios Oncology Nutrition, LLCInventor: Peter Meade Anderson
-
Patent number: 9839640Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: GrantFiled: November 10, 2011Date of Patent: December 12, 2017Assignee: OccuRx Pty LtdInventors: Darren James Kelly, David Stapleton
-
Patent number: 9833426Abstract: An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient.Type: GrantFiled: June 28, 2013Date of Patent: December 5, 2017Assignee: Kyowa Hakko Bio Co., Ltd.Inventors: Masahiko Morita, Miho Yin Komatsu, Takahiro Hara
-
Patent number: 9526713Abstract: Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects.Type: GrantFiled: May 24, 2013Date of Patent: December 27, 2016Assignee: KUNMING SHENGHUO PHARMACEUTICAL (GROUP) CO., LTD.Inventors: Guihua Lan, Feng Lan, Xiaobo Sun
-
Patent number: 9518008Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.Type: GrantFiled: October 10, 2014Date of Patent: December 13, 2016Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
-
Patent number: 9447028Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.Type: GrantFiled: October 9, 2015Date of Patent: September 20, 2016Assignee: King's College LondonInventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
-
Patent number: 9409856Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.Type: GrantFiled: June 8, 2015Date of Patent: August 9, 2016Assignee: Gtx, Inc.Inventors: James T. Dalton, Christina Herring, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
-
Patent number: 9402864Abstract: Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.Type: GrantFiled: June 9, 2011Date of Patent: August 2, 2016Assignee: EMISPHERE TECHNOLOGIES, INC.Inventors: Gary M. Riley, Parshuram Rath, Michael Novinski
-
Patent number: 9381196Abstract: The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.Type: GrantFiled: March 19, 2015Date of Patent: July 5, 2016Assignee: The Translational Genomics Research InstituteInventors: Tong Wang, Stephen Gately
-
Patent number: 9375438Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SURI and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.Type: GrantFiled: September 27, 2013Date of Patent: June 28, 2016Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Dept. of Veterans AffairsInventor: J. Marc Simard
-
Patent number: 9278062Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.Type: GrantFiled: September 29, 2010Date of Patent: March 8, 2016Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
-
Patent number: 9272992Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.Type: GrantFiled: August 16, 2013Date of Patent: March 1, 2016Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
-
Patent number: 9254271Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.Type: GrantFiled: April 8, 2009Date of Patent: February 9, 2016Assignee: Omeros CorporationInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Patent number: 9248186Abstract: A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.Type: GrantFiled: October 30, 2012Date of Patent: February 2, 2016Assignee: BINYARCO, LLCInventor: Jeffrey E. Binder
-
Patent number: 9233089Abstract: Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) inhibitors.Type: GrantFiled: March 15, 2013Date of Patent: January 12, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark R. Nicolls, Wen Tian, Jayakumar Rajadas